New antibody studies boost hope for HIV cure: Pioneering trials discover potential strategy to keep virus in check after stopping treatment
Antibody studies offer new hope for HIV prevention, cure: The Conference on Retroviruses and Opportunistic Infections highlighted promising advancements in HIV research amid funding cuts. Gilead Sciences presented data showing a single injection of lenacapavir could prevent HIV for a year, surpassing previous pre-exposure prophylaxis methods. Additionally, studies on broadly neutralizing antibodies demonstrated potential in controlling HIV without antiretroviral drugs, with some participants maintaining viral suppression for extended periods.